- Home
- RELI vs VIVS Comparison
RELI vs VIVS Comparison
Compare RELI & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RELI
- VIVS
- Stock Information
- Founded
- RELI 2013
- VIVS 2007
- Country
- RELI United States
- VIVS United States
- Employees
- RELI N/A
- VIVS N/A
- Industry
- RELI Specialty Insurers
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RELI Finance
- VIVS Health Care
- Exchange
- RELI Nasdaq
- VIVS Nasdaq
- Market Cap
- RELI 3.0M
- VIVS 3.1M
- IPO Year
- RELI N/A
- VIVS N/A
- Fundamental
- Price
- RELI $1.22
- VIVS $2.07
- Analyst Decision
- RELI
- VIVS
- Analyst Count
- RELI 0
- VIVS 0
- Target Price
- RELI N/A
- VIVS N/A
- AVG Volume (30 Days)
- RELI 54.9K
- VIVS 387.4K
- Earning Date
- RELI 05-14-2025
- VIVS 05-30-2025
- Dividend Yield
- RELI N/A
- VIVS N/A
- EPS Growth
- RELI N/A
- VIVS N/A
- EPS
- RELI N/A
- VIVS N/A
- Revenue
- RELI $14,208,143.00
- VIVS $122,000.00
- Revenue This Year
- RELI N/A
- VIVS $59.08
- Revenue Next Year
- RELI N/A
- VIVS $18.24
- P/E Ratio
- RELI N/A
- VIVS N/A
- Revenue Growth
- RELI 2.40
- VIVS N/A
- 52 Week Low
- RELI $0.97
- VIVS $1.56
- 52 Week High
- RELI $18.53
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- RELI 55.58
- VIVS N/A
- Support Level
- RELI $1.01
- VIVS N/A
- Resistance Level
- RELI $1.33
- VIVS N/A
- Average True Range (ATR)
- RELI 0.09
- VIVS 0.00
- MACD
- RELI 0.02
- VIVS 0.00
- Stochastic Oscillator
- RELI 65.63
- VIVS 0.00
About RELI Reliance Global Group Inc.
Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing acquisition strategies, initially and focused on wholesale and retail insurance agencies. Its primary strategies is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.